IGF2BP1–THBS1 Axis Regulates Macrophage Metabolism in Pulmonary Fibrosis

Study Background and Research Question

Pulmonary fibrosis (PF) is a progressive and often fatal lung disorder characterized by excessive extracellular matrix (ECM) deposition, fibroblast proliferation, and chronic inflammation, leading to irreversible loss of lung function. Although the etiopathogenesis of PF remains incompletely understood, macrophages are recognized as central mediators of both fibrotic and inflammatory responses, balancing tissue injury and repair. Macrophages can polarize into M1 (pro-inflammatory) or M2 (pro-fibrotic) phenotypes, with the latter implicated in exacerbating fibrosis through the secretion of fibrogenic mediators and modulation of the tissue microenvironment. Recent focus has turned to the role of metabolic reprogramming—especially glycolytic activation—in promoting macrophage-driven fibrosis. Meanwhile, epigenetic modifications such as N6-methyladenosine (m6A) have emerged as important regulators of RNA stability and cellular phenotype. However, the precise molecular mechanisms by which m6A readers such as insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) coordinate macrophage function and metabolism in PF remain undefined (paper).

Key Innovation from the Reference Study

The referenced study provides a mechanistic breakthrough by identifying that IGF2BP1, an m6A reader, promotes pulmonary fibrosis via stabilization of thrombospondin-1 (THBS1) mRNA. This stabilization enhances glycolytic metabolism and drives macrophage polarization toward the M2 phenotype, which is closely associated with fibrotic progression. The work further demonstrates that THBS1 interacts with toll-like receptor 4 (TLR4), forming a functional IGF2BP1/THBS1/TLR4 regulatory axis. This axis orchestrates metabolic and phenotypic reprogramming in macrophages, thereby exacerbating pulmonary fibrosis (paper).

Methods and Experimental Design Insights

The investigators employed a multi-tiered approach, combining in vivo and in vitro analyses to dissect the molecular and cellular events underpinning PF:

• In vivo mouse model: Bleomycin-induced pulmonary fibrosis in mice was used to simulate PF pathophysiology. IGF2BP1 expression was manipulated via genetic knockdown strategies.
• Histopathological assessment: Lung tissues were evaluated for cellular infiltration, fibroblast accumulation, Ashcroft fibrosis scoring, and hydroxyproline quantification—providing both morphological and biochemical readouts of fibrosis severity.
• Immunophenotyping and molecular assays: Flow cytometry and immunohistochemistry were used to quantify macrophage subsets (CD68+, CD163+), while qPCR and Western blotting assessed the expression of fibrosis- and inflammation-associated markers (TGF-β1, α-SMA, Collagen I/III, Arg1, CCL18, Ym1, IL-6, IL-1β, and TIMP1).
• RNA-protein interaction studies: RNA immunoprecipitation and m6A mapping elucidated the binding of IGF2BP1 to m6A-modified THBS1 transcripts.
• Functional rescue experiments: Overexpression of THBS1 and TLR4 in macrophages was used to examine their ability to reverse the effects of IGF2BP1 or THBS1 knockdown on M2 polarization and glycolytic metabolism.
• Metabolic profiling: Glycolysis was monitored via measurement of glycolytic enzyme expression (HK2, LDHA, PKM2), lactate/glucose consumption, and ATP production.

Protocol Parameters

• assay | Bleomycin-induced pulmonary fibrosis model | standard: 1–2 mg/kg bleomycin, intratracheal | Applicability: Murine PF pathogenesis studies | Rationale: Robustly induces fibrosis and macrophage activation | source: paper
• assay | Macrophage polarization (M2) quantification | CD68+/CD163+ proportion via flow cytometry | Applicability: Fibrosis-associated M2 macrophage studies | Rationale: CD163 marks pro-fibrotic M2 macrophages | source: paper
• assay | Glycolytic enzyme expression | qPCR/WB for HK2, LDHA, PKM2 | Applicability: Metabolic reprogramming in macrophages | Rationale: Glycolytic shift is central to M2 polarization | source: paper
• assay | Recombinant cytokine stimulation (M-CSF) | 10–50 ng/mL, 24–72 h | Applicability: In vitro macrophage differentiation | Rationale: Supports reproducible macrophage expansion and polarization | source: workflow_recommendation

Core Findings and Why They Matter

Key discoveries from this study include:

• IGF2BP1 overexpression in PF macrophages: Elevated IGF2BP1 levels in macrophages from fibrotic lungs were linked to increased disease severity.
• Attenuation of fibrosis via IGF2BP1 knockdown: Reducing IGF2BP1 expression led to less inflammatory cell infiltration, lower fibrosis scores, and decreased ECM deposition, along with a reduction in pro-fibrotic and inflammatory marker expression (paper).
• m6A-dependent stabilization of THBS1 mRNA: IGF2BP1 was shown to bind and stabilize THBS1 transcripts in an m6A-dependent manner, promoting THBS1 protein expression in macrophages.
• THBS1’s role in M2 polarization and glycolysis: Overexpression of THBS1 rescued the impaired M2 polarization and glycolytic activity seen with IGF2BP1 knockdown, restoring glycolytic enzyme levels and cellular energy metabolism.
• THBS1–TLR4 interaction: THBS1 physically interacted with TLR4; overexpression of TLR4 similarly reversed the effects of THBS1 knockdown, highlighting the cooperative nature of this axis in driving M2 polarization and metabolic reprogramming.

These findings advance the understanding of macrophage-mediated fibrogenesis by linking posttranscriptional m6A regulation to metabolic reprogramming and pro-fibrotic phenotype acquisition. Targeting this IGF2BP1/THBS1/TLR4 axis may offer new therapeutic angles in PF, particularly in modulating macrophage activation and cytokine release, glycolytic metabolism, and downstream fibrosis (paper).

Comparison with Existing Internal Articles

Several internal resources contextualize these findings within broader macrophage and fibrosis research workflows:

• The article “Recombinant Mouse M-CSF: Mechanistic Insight and Strategic Application” discusses the pivotal role of Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) as a driver of macrophage survival, proliferation, and polarization, which directly aligns with the need for robust in vitro macrophage models as seen in the reference study. Notably, the IGF2BP1–THBS1 axis manipulates macrophage phenotype downstream of growth factor priming (workflow_recommendation).
• “Applied Workflows for Recombinant Mouse M-CSF in Macrophage Research” details best practices for macrophage expansion and differentiation with high-purity, tag-free recombinant cytokines. These protocols are foundational for modeling macrophage behavior in vitro, such as the polarization and metabolic assays used in the reference paper (workflow_recommendation).
• The article “IGF2BP1–THBS1 Axis Drives Macrophage Metabolic Reprogramming in Pulmonary Fibrosis” provides a focused summary of the same central mechanism, reinforcing the evidence for this regulatory pathway in PF and highlighting its role in inflammatory response modulation and macrophage-mediated tumor cell killing as broader research themes.

Limitations and Transferability

While the reference study provides compelling mechanistic evidence in murine models and primary macrophage cultures, several limitations constrain direct clinical translation. First, the reliance on bleomycin-induced PF may not recapitulate all aspects of human idiopathic pulmonary fibrosis. Second, the in vitro macrophage polarization and glycolysis assays, though informative, may not fully account for complex tissue and immune interactions in vivo. Additionally, the molecular targets identified (IGF2BP1, THBS1, TLR4) require further validation in human tissues and disease models. Transferability to other fibrotic conditions or organ systems should be approached with caution and empirical validation (paper).

Research Support Resources

For researchers aiming to reproduce or extend these findings, robust in vitro macrophage models are essential. Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) without Tag (SKU PM2021) from APExBIO provides a validated, species-specific reagent facilitating macrophage differentiation, survival, and functional assays in mouse systems (source: product_spec). Integrated with literature-backed protocols and best-practice recommendations, this reagent supports the development of reproducible macrophage activation, polarization, and metabolic assays for PF and related research.